BioCryst Pharmaceuticals Inc
F:BO1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioCryst Pharmaceuticals Inc
F:BO1
|
US |
|
S
|
Sirona Biochem Corp
XBER:ZSB
|
CA |
|
Shanghai Electric Group Co Ltd
OTC:SIELF
|
CN |
|
Entergy Corp
NYSE:ETR
|
US |
|
L
|
London Stock Exchange Group PLC
F:LS4C
|
UK |
|
M
|
Mentice AB
STO:MNTC
|
SE |
|
AVITA Medical Inc
NASDAQ:RCEL
|
US |
|
R
|
Ramaco Resources Inc
NASDAQ:METCB
|
US |
|
T
|
Tortilla Mexican Grill PLC
F:73D
|
UK |
|
R
|
Rathbones Group PLC
OTC:RTBBF
|
UK |
|
P
|
Prudential PLC
F:PRU2
|
UK |
|
Nippon Telegraph and Telephone Corp
TSE:9432
|
JP |
|
CAVA Group Inc
NYSE:CAVA
|
US |
|
F
|
Fairfax Financial Holdings Ltd
TSX:FFH.U
|
CA |
|
W
|
Wang On Group Ltd
XMUN:WON1
|
HK |
|
Pacific Ridge Exploration Ltd
XTSX:PEX
|
CA |
|
S
|
Shanghai Electric Group Co Ltd
XMUN:USR
|
CN |
|
L
|
Lonking Holdings Ltd
F:C9IB
|
CN |
|
Unibail-Rodamco-Westfield SE
PAR:URW
|
FR |
|
T
|
thyssenkrupp nucera AG & Co KgaA
F:NCH2
|
DE |
|
M
|
Mitek Systems Inc
F:MKQ
|
US |
|
T
|
Takeda Pharmaceutical Co Ltd
SWB:TKD
|
JP |
|
P
|
Prudential PLC
F:PRU
|
UK |
Wall St Price Targets
BO1 Price Targets Summary
BioCryst Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for BO1 is 15.129 EUR with a low forecast of 8.934 EUR and a high forecast of 22.861 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BO1's stock price target?
Price Target
15.129
EUR
According to Wall Street analysts, the average 1-year price target for BO1 is 15.129 EUR with a low forecast of 8.934 EUR and a high forecast of 22.861 EUR.
What is the Revenue forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 8 years is 9%.
What is the Gross Profit forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 31%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
10%
The compound annual growth rate for Operating Income over the next 8 years is 10%.
What is the Pre-Tax Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
-7%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -7%.
What is the Net Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
20%
The compound annual growth rate for Net Income over the next 8 years is 20%.
